- Home
- CELU vs INMB Comparison
CELU vs INMB Comparison
Compare CELU & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- INMB
- Stock Information
- Founded
- CELU 2016
- INMB 2015
- Country
- CELU United States
- INMB United States
- Employees
- CELU N/A
- INMB N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- INMB Health Care
- Exchange
- CELU Nasdaq
- INMB Nasdaq
- Market Cap
- CELU 56.9M
- INMB 49.2M
- IPO Year
- CELU N/A
- INMB 2019
- Fundamental
- Price
- CELU $1.96
- INMB $1.71
- Analyst Decision
- CELU Strong Buy
- INMB Hold
- Analyst Count
- CELU 1
- INMB 3
- Target Price
- CELU $6.00
- INMB $4.30
- AVG Volume (30 Days)
- CELU 69.1K
- INMB 382.6K
- Earning Date
- CELU 11-14-2025
- INMB 10-30-2025
- Dividend Yield
- CELU N/A
- INMB N/A
- EPS Growth
- CELU N/A
- INMB N/A
- EPS
- CELU N/A
- INMB N/A
- Revenue
- CELU $40,578,000.00
- INMB $50,000.00
- Revenue This Year
- CELU N/A
- INMB $191.43
- Revenue Next Year
- CELU $76.00
- INMB $12,299.51
- P/E Ratio
- CELU N/A
- INMB N/A
- Revenue Growth
- CELU N/A
- INMB 19.05
- 52 Week Low
- CELU $1.00
- INMB $1.38
- 52 Week High
- CELU $4.35
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- CELU 57.50
- INMB 55.44
- Support Level
- CELU $1.62
- INMB $1.46
- Resistance Level
- CELU $2.29
- INMB $1.62
- Average True Range (ATR)
- CELU 0.15
- INMB 0.10
- MACD
- CELU 0.06
- INMB 0.03
- Stochastic Oscillator
- CELU 63.29
- INMB 97.14
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.